A randomized, double-blind, placebo-controlied trial of subcutaneous etanercept (p75 souble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohns' disease
- 30 April 2001
- journal article
- abstracts
- Published by Elsevier in Gastroenterology
- Vol. 120 (5) , A20
- https://doi.org/10.1016/s0016-5085(08)80100-x
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: